Sanofi SA said Monday that it will acquire biotechnology company Synthorx Inc. for an aggregated equity value of around $2.5 billion.
The French pharmaceutical company SAN, -0.50% SNY, -0.11% said it plans to take control of all outstanding shares of Synthorx THOR, +0.20% for $68 per share in cash.
The acquisition of Synthorx, which is expected to close in the first quarter next year, will strengthen Sanofi’s existing immuno-oncology portfolio, it said.
The takeover is “aligned with our goal to build our oncology franchise with potentially practice-changing medicines and novel combinations,” Sanofi’s Chief Executive Paul Hudson said.
Business - Latest - Google News
December 09, 2019 at 04:07PM
https://ift.tt/2P1sES5
Sanofi to acquire Synthorx for $2.5 billion - MarketWatch
Business - Latest - Google News
https://ift.tt/2Rx7A4Y
Bagikan Berita Ini
0 Response to "Sanofi to acquire Synthorx for $2.5 billion - MarketWatch"
Post a Comment